Clinical Trials Sponsored by GlycoMimetics Incorporated

Total 1169 results

GlycoMimetics Incorporated

Completed

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

Healthy Adult Subjects

United States
GlycoMimetics Incorporated

Terminated

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia | Vaso-occlusive Crisis | Pain Crisis | Sickle Cell Disorders

United States, Canada
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Healthy

United States
GlycoMimetics Incorporated

Completed

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Sickle Cell Disease

United States
GlycoMimetics Incorporated

Completed

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Leukemia, Myeloid, Acute

United States, Ireland, Australia
GlycoMimetics Incorporated
Celerion

Completed

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Healthy Volunteers

United States
GlycoMimetics Incorporated

Active, not recruiting

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Canada, Spain, Australia, Netherlands, France, Ireland, Italy, United Kingdom
GlycoMimetics Incorporated

Terminated

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Breast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast Cancer

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
GlycoMimetics Incorporated

Completed

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Anemia, Sickle Cell

United States, Canada
GlycoMimetics Incorporated

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Healthy

Belgium
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Healthy

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Healthy | Renal Impairment

United States
GlycoMimetics Incorporated

Completed

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Sickle Cell Disease | Vaso-occlusive Crisis | Pain Crisis

United States, Canada
GlycoMimetics Incorporated

Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Multiple Myeloma

Ireland, Denmark, United Kingdom, Germany
GlycoMimetics Incorporated
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Healthy

United States
GlycoMimetics Incorporated
Quotient Sciences

Completed

A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)

Healthy Subjects

United Kingdom
GlycoMimetics Incorporated
University of Michigan

Terminated

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Deep Venous Thrombosis

United States
GlycoMimetics Incorporated
University of Michigan

Completed

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Healthy Volunteers

United States
Lena Napolitano, MD
GlycoMimetics Incorporated

Terminated

Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

COVID-19 Pneumonia

United States
Malika Kapadia
GlycoMimetics Incorporated

Recruiting

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Acute Myeloid Leukemia | Pediatric Cancer

United States
Brian Jonas
National Cancer Institute (NCI); GlycoMimetics Incorporated

Recruiting

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; GlycoMimetics Incorporated

Completed

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

Multiple Myeloma

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Inguinal Hernia Study Using Biodesign IHM

Inguinal Hernia

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery

Obesity | Hernia

United States
Cook Research Incorporated

Recruiting

Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered

Esophageal Diseases

Germany, Spain, United Kingdom
Cook Research Incorporated

Recruiting

Zenith® Fenestrated+ Clinical Study

Aortic Aneurysm, Abdominal | Juxtarenal Aortic Aneurysm | Extent IV Thoracoabdominal | Pararenal Aneurysm

United States
Cook Research Incorporated

Recruiting

Biodesign® Otologic Repair Graft

Tympanic Membrane Perforation | Eardrum Perforation

United States
Cook Research Incorporated

Completed

Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients

Liver Cirrhosis

Belgium, Spain, Netherlands
Cook Research Incorporated

Completed

Zenith® p-Branch® and Zenith® Fenestrated AAA Endovascular Graft Clinical Study (FENP)

Aortic Aneurysm, Abdominal

United States
Cook Research Incorporated

Completed

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Liver Diseases | Liver Cirrhosis | Hypertension, Portal

United States, Australia, Hong Kong
Cook Research Incorporated

Completed

Zilver® PTX® V Clinical Study

Peripheral Arterial Disease

United States
Cook Research Incorporated

Completed

Zenith TX2® Post-market Approval Study (TX2 2PAS)

Descending Thoracic Aortic Aneurysm

United States, Canada
Cook Research Incorporated

Completed

Zenith® Dissection Clinical Trial

Aortic Dissection

United States, Japan
Cook Research Incorporated

Terminated

HemaTrate™ in the Treatment of Critical Limb Ischemia

Ischemia | Critical Limb Ischemia

United Kingdom
Cook Research Incorporated

Completed

Cook Enforcer Post-Market Study

End-Stage Renal Disease

United States
Cook Group Incorporated
Cook Biotech Incorporated

Terminated

Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (SurgiSIS AFP)

Crohn's Disease | Anal Fistula

United States
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Insmed Incorporated

Available

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Healthy Volunteers

United States
Lenstec Incorporated

Completed

Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens

Presbyopia | Cataracts

United States
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Insmed Incorporated

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

Healthy Volunteers

United States
Celularity Incorporated

Active, not recruiting

CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States
VertiFlex, Incorporated

Completed

The STEPS - Totalis™ Trial

Lumbar Spinal Stenosis

United States
Celularity Incorporated

Completed

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Multiple Myeloma

United States

Clinical Trials Sponsored by GlycoMimetics Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations